This website uses cookies to provide you with the best experience. By using this site you agree to our use of cookies. Please read our cookie notice for more information.

« Back

ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting

July 25, 2016

DUBLIN--(BUSINESS WIRE)-- ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on July 22, 2016 (which resolutions had all been recommended by the Board) were all duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 10, 2016 and are available on the ICON plc website.

The final results of the voting are as follows:

1.1 To re-elect Prof. William Hall 44,598,786 43,441,419 1,107,356 50,011
1.2 To re-elect Dr. John Climax 44,598,786 41,638,547 2,910,103 50,136
1.3 To re-elect Dr. Steve Cutler 44,598,786 41,684,537 2,864,038 50,211
2 To receive accounts and reports 44,598,786 44,342,023 20,582 236,181
3 To authorise the fixing of the auditors' remuneration 44,598,786 40,370,214 4,172,535 56,037
4** To authorise the Company to allot shares 44,598,786 43,504,876 1,039,052 54,858
5** To disapply pre-emption rights 44,598,786 44,442,367 87,421 68,998
6** To authorise the Company to make market purchases of shares 44,598,786 44,319,050 227,316 52,420
7** To authorise the price range at which the Company can reissue shares it holds as treasury shares 44,598,786 44,501,150 42,100 55,536
8** To authorise the amendment of the Company's Articles of Association 44,598,786 44,505,437 29,425 63,924
9** To authorise the amendment of the Company's Memorandum of Association 44,598,786 44,504,416 29,873 64,497

** Special Resolution. All resolutions are ordinary resolutions unless otherwise stated.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at

ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 89 locations in 37 countries and has approximately 12,300 employees. Further information is available at

Source: ICON plc

All at ICON.


ICON plc
Investor Relations
Brendan Brennan, Chief Financial Officer
+ 353 -1-291-2000
Simon Holmes, EVP Investor Relations and Corporate Development
+ 353 -1-291-2000

Source: ICON plc ICON plc

News Provided by Acquire Media

Search Investor